Clinical Trials Logo

Hepatitis C Infection clinical trials

View clinical trials related to Hepatitis C Infection.

Filter by:

NCT ID: NCT01016912 Completed - Clinical trials for Hepatitis C Infection

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to identify at least 1 dose of daclatasvir that is safe, well tolerated, and efficacious when combined with peginterferon-alfa and ribavirin for the treatment of hepatitis C virus genotype 1 in chronically infected patients who are treatment-naïve and nonresponsive to the standard of care

NCT ID: NCT00991289 Completed - HIV Infection Clinical Trials

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Start date: January 2010
Phase: Phase 2
Study type: Interventional

Infection with hepatitis C virus (HCV) can cause liver scarring, or cirrhosis, and this usually occurs more rapidly among people infected with both HCV and human immunodeficiency virus (HIV). People infected with both HCV and HIV have poor response to the current HCV treatments. This phase II pilot study evaluated whether adding a new HCV medication improves response to the current standard HCV treatment with pegylated interferon and ribavirin in people with both HCV and HIV.

NCT ID: NCT00874770 Completed - Clinical trials for Hepatitis C Infection

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.

NCT ID: NCT00841477 Completed - HIV Infection Clinical Trials

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

Start date: January 2004
Phase: Phase 3
Study type: Interventional

The goal of the proposed study is to use the HBV vaccine as a model for a future HIV vaccine trial, examining the efficacy of community-based outreach intervention as well as an accelerated vaccine schedule as a method for increasing acceptance/adherence with HBV vaccination protocols among not-in-treatment drug users. This study will also examine the effect of HBV vaccination coupled with community-based outreach intervention on reducing the incidence of HIV, HBV and HCV infections and the frequency of needle use and sexual risk behaviors related to these viral transmissions. A secondary purpose will be to assess the antibody response after HBV vaccination as a measurement of immunological response in drug users.

NCT ID: NCT00513461 Completed - Clinical trials for Hepatitis C Infection

Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection

Start date: October 2007
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) works compared to a placebo in preventing liver cancer in patients with chronic hepatitis C infection. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of SAMe may keep cancer from forming in patients with advanced liver disease